OBI Pharma
OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has co… Read more
OBI Pharma (4174) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.132x
Based on the latest financial reports, OBI Pharma (4174) has a cash flow conversion efficiency ratio of -0.132x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-407.43 Million) by net assets (NT$3.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OBI Pharma - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how OBI Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
OBI Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OBI Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orion Office Reit Inc
NYSE:ONL
|
0.009x |
|
JEIO CO LTD (PROPOSED)
KQ:418550
|
0.000x |
|
JAPFA LTD
F:1O4
|
N/A |
|
SciVision Biotech Inc
TW:1786
|
0.008x |
|
Jiangsu Cowin Biotech Co. Ltd. A
SHG:688426
|
N/A |
|
XRF Scientific Ltd
AU:XRF
|
0.104x |
|
Ca Toulouse 31 CCI
PA:CAT31
|
0.018x |
|
EVI INDS INC. DL-025
F:2YE
|
N/A |
Annual Cash Flow Conversion Efficiency for OBI Pharma (2011–2024)
The table below shows the annual cash flow conversion efficiency of OBI Pharma from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$4.82 Billion | NT$-1.83 Billion | -0.380x | -13.99% |
| 2023-12-31 | NT$4.95 Billion | NT$-1.65 Billion | -0.334x | -26.42% |
| 2022-12-31 | NT$6.14 Billion | NT$-1.62 Billion | -0.264x | +4.01% |
| 2021-12-31 | NT$3.87 Billion | NT$-1.06 Billion | -0.275x | +17.34% |
| 2020-12-31 | NT$4.84 Billion | NT$-1.61 Billion | -0.333x | -65.38% |
| 2019-12-31 | NT$5.20 Billion | NT$-1.05 Billion | -0.201x | -4.12% |
| 2018-12-31 | NT$4.47 Billion | NT$-864.31 Million | -0.193x | +11.67% |
| 2017-12-31 | NT$5.06 Billion | NT$-1.11 Billion | -0.219x | -60.41% |
| 2016-12-31 | NT$6.16 Billion | NT$-840.10 Million | -0.136x | -163.20% |
| 2015-12-31 | NT$7.18 Billion | NT$-372.20 Million | -0.052x | +83.89% |
| 2014-12-31 | NT$1.44 Billion | NT$-464.22 Million | -0.322x | -495.51% |
| 2013-12-31 | NT$1.93 Billion | NT$-104.16 Million | -0.054x | +61.92% |
| 2012-12-31 | NT$829.77 Million | NT$-117.64 Million | -0.142x | +85.82% |
| 2011-12-31 | NT$508.44 Million | NT$-508.22 Million | -1.000x | -- |